Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

United Therapeutics (UTHR) Free Cash Flow (2016 - 2026)

United Therapeutics' Free Cash Flow history spans 17 years, with the latest figure at $173.3 million for Q4 2025.

On a quarterly basis, Free Cash Flow fell 31.91% to $173.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 3.69% decrease, with the full-year FY2025 number at $1.0 billion, down 3.69% from a year prior.
Free Cash Flow hit $173.3 million in Q4 2025 for United Therapeutics, down from $351.6 million in the prior quarter.
Over the last five years, Free Cash Flow for UTHR hit a ceiling of $397.4 million in Q3 2023 and a floor of -$44.9 million in Q4 2023.
Historically, Free Cash Flow has averaged $212.6 million across 5 years, with a median of $217.0 million in 2021.
Biggest five-year swings in Free Cash Flow: tumbled 121.08% in 2023 and later surged 666.82% in 2024.
Tracing UTHR's Free Cash Flow over 5 years: stood at $221.1 million in 2021, then fell by 3.66% to $213.0 million in 2022, then tumbled by 121.08% to -$44.9 million in 2023, then surged by 666.82% to $254.5 million in 2024, then tumbled by 31.91% to $173.3 million in 2025.
Business Quant data shows Free Cash Flow for UTHR at $173.3 million in Q4 2025, $351.6 million in Q3 2025, and $129.5 million in Q2 2025.